Important information of covid 19 and healthcare tips how to recover from corona virus

Cyrus Poonawalla of Pune-based Serum Institute of India (SII), the world’s largest vaccine producer by the number of doses manufactured, entered the Forbes List of India’s 100 richest that was released amid the outbreak of Covid-19. Cyrus Poonawalla was at the  sixth spot on the coveted list . “Amid the Covid-19 pandemic which hit India hard and led to a sharp economic contraction, half of the nation’s 100 richest on the 2020 Forbes India Rich List saw gains,” Forbes said. Cyrus Poonawalla’s son Adar Poonawalla is the current CEO of SII. He joined the company his father started in 1966, after graduating from the University of Westminster in 2001. SII has been in the spotlight for the past few months as it is to manufacture the coronavirus vaccine developed by Oxford University’s Jenner Institute and AstraZeneca in India. It began trials in the country in August-end and in last week of September, the third phase of  human clinical trial  began at the state-run Sassoon G...

India has registered more than 50,000 Covid-19 deaths, overtaking the UK to become the fourth-worst-affected country for fatalities. But the number of deaths per million people stands at 34 - far lower than what has been reported in Europe or North America. The case fatality rate or CFR, which measures deaths among Covid-19 patients, is just around 2%. Even in badly-hit state like Maharashtra the number of deaths is doubling only in about 40 days. "The death rates have kept low all along, even as cases rose," K Srinath Reddy, president of the Public Health Foundation of India think tank, told me. Many epidemiologists attribute this relatively low fatality rate to a young population - the elderly are typically more vulnerable. It is not clear whether other factors, such as immunity deriving from previous infections from other coronaviruses, are also responsible. Also, they point to a pattern of low mortality in South Asian countries that share a similar demograp...

Since the beginning of the COVID-19 pandemic, the Chinese Communist Party supported by some Western scientists and a politically-motivated media have desperately tried to convince the world that the COVID-19 virus originated as a bat beta-coronavirus which underwent a natural mutation process and was then acquired by humans after exposure to infected animals. Undoubtedly, such subterfuge is meant to protect certain vested interests, including the potentially devastating political and economic consequences for China, global corporate and private investment in China and a negative effect on scientific collaboration and research funding of major Western research laboratories. In her first article, “Unusual Features of the SARS-CoV-2 Genome Suggesting Sophisticated Laboratory Modification Rather Than Natural Evolution and Delineation of Its Probable Synthetic Route,” Chinese scientist and whistleblower, Dr. Li-Meng Yan presented the biological evidence demonstrating that the COVID-19 vir...

In yet another discovery about the way in which Covid-19 affects children, doctors in Bengaluru are finding that they sometimes develop certain symptoms nearly a month after they recover from the disease.  The case of a 9-year-old child brought to Aster CMI Hospital with multi-system inflammatory syndrome (MIS) on Tuesday, 45 days after recovering from Covid-19 took doctors by surprise.   “We are seeing children come down with MIS, atypical Kawasaki Disease, or toxic shock syndrome, around 30-45 days after getting Covid. MIS is an intense inflammatory reaction to the virus.  However, we still don’t know why the symptoms appear 30-45 after they recover from Covid-19,” said Dr Srikanta J T, paediatric pulmonology consultant at Aster Hospital.  Similarly, doctors at Columbia Asia Referral Hospital in Yeshwantpur came across a 12-year-old boy with severe abdominal pain, high fever, high inflammatory markers, chest pain and cardiac changes. Doctors suspected the sy...

Drug firm  Glenmark Pharmaceuticals  on Friday said the addition of  antiviral Umifenovir  did not demonstrate any significant clinical benefit over  Favipiravir   alone in  moderate COVID-19 patients .  The  clinical study  evaluated the possible superiority of the combination's efficacy against Favipiravir monotherapy, Glenmark said in a statement. As per the results that Glenmark presented to the regulator, the study showed no superior clinical outcomes with the addition of Umifenovir, it added. This was the second clinical study after the successful Favipiravir monotherapy trial earlier this year that led the company to receiving the Emergency Use Authorisation for Favipiravir, Glenmark said. "These latest findings confirm that the addition of Umifenovir does not show any incremental benefit in clinical outcomes. Thus Favipiravir therapy along with supportive care remains a suitable and effective choice for mild to moderate COVID-...

Drug firm  Glenmark Pharmaceuticals  on Friday said the addition of  antiviral Umifenovir  did not demonstrate any significant clinical benefit over  Favipiravir  alone in  moderate COVID-19 patients .  The  clinical study  evaluated the possible superiority of the combination's efficacy against Favipiravir monotherapy, Glenmark said in a statement. As per the results that Glenmark presented to the regulator, the study showed no superior clinical outcomes with the addition of Umifenovir, it added. This was the second clinical study after the successful Favipiravir monotherapy trial earlier this year that led the company to receiving the Emergency Use Authorisation for Favipiravir, Glenmark said. "These latest findings confirm that the addition of Umifenovir does not show any incremental benefit in clinical outcomes. Thus Favipiravir therapy along with supportive care remains a suitable and effective choice for mild to moderate COVID-1...

Glenmark Pharmaceuticals Ltd on Friday said addition of Umifenovir did not demonstrate any additional benefit over Favipiravir alone in moderate Covid-19 patients. Umifenovir did not show superior clinical outcomes when added to Favipiravir treatment, the trial did not meet key end-points,  the company said. The trial's findings confirm that the addition of Umifenovir does not show any incremental benefit in clinical outcomes, Monika Tandon, senior vice president & head, Clinical Development, Global Specialty/Branded Portfolio at the company, said in a statement , adding that favipiravir alone remains the effective choice for mild to moderate COVID-19 infection. Favipiravir is made under the brand name Avigan by Japan's Fujifilm Holdings Corp and was approved for use as an anti-flu drug there in 2014, while Umifenovir is licensed as a treatment for some types of flu infections in Russia and China. Fujifilm last month said a late-stage study of Avigan showed i...